USPTO Examiner BERRIOS JENNIFER A - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18443353PERSONAL CARE COMPOSITION COMPRISING WATER INSOLUBLE SOLID ORGANIC COMPOUNDFebruary 2024September 2024Allow700YesNo
18231455MITOCHONDRIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND HAIRAugust 2023January 2025Abandon1810NoNo
18217298COSMETIC OIL THICKENER AND OIL-SOLUBLE COPOLYMERJune 2023March 2025Allow2111YesNo
18316360SILK FIBROIN BIOCOMPATIBLE POLYURETHANE MEMBRANESMay 2023April 2025Allow2321YesNo
18165311METHOD OF USING A STYE TREATMENT FORMULATION TO TREAT AT LEAST ONE STYE, AT LEAST ONE CHALAZION, BLEPHARITIS, OR ANY COMBINATION THEREOFFebruary 2023August 2024Abandon1810NoNo
18078902BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMESDecember 2022October 2024Abandon2211NoNo
17993604EMULSIFYING COMPOSITION FOR COSMETIC USE FOR PRODUCING AN O/W PICKERING EMULSION AND PROCESS FOR PRODUCING THIS EMULSIONNovember 2022March 2025Abandon2821NoNo
17965628HIGH-POTENCY VITAMIN C AND SUGAR ALCOHOL TOPICAL FORMULATIONSOctober 2022March 2024Allow1821YesNo
17934813Particles for Targeted Delivery and Uses in Managing Bleeding or Blood ClottingSeptember 2022March 2023Allow600NoNo
17759666EXTERNAL SKIN PREPARATIONJuly 2022June 2025Allow3520YesNo
17873515Method of Thickening Cosmetic CompositionJuly 2022April 2024Abandon2121NoNo
17808978COMPOSITIONS AND METHODS FOR WOUND TREATMENTJune 2022March 2024Allow2111YesNo
17752671COSMETIC COMPOSITIONS IN PARTICULAR WITH ANTI-AGING EFFECT, COMPRISING A GREEN EXTRACT OF AFRAMOMUM ANGUSTIFOLIUM OR LONGOZA PLANTMay 2022August 2024Abandon2740YesNo
17658707ORAL BACLOFEN SOLUTIONSApril 2022July 2024Abandon2730NoNo
17658255STYE TREATMENT FORMULATION AND METHODS OF USE THEREOFApril 2022May 2023Abandon1420YesNo
17713717ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENTApril 2022April 2024Abandon2411NoNo
17623810ORAL CARE GUMMIESDecember 2021April 2025Abandon3901NoNo
17561631CIPROFLOXACIN OPHTHALMIC TOPICAL COMPOSITION FOR TREATING OCULAR DISEASEDecember 2021March 2023Allow1520NoNo
17619464EXTENDED-RELEASE SOLID ORAL DOSAGE FORM COMPRISING VITAMIN B12 AND A VITAMIN B12 DEPLETING DRUGDecember 2021February 2025Abandon3801NoNo
17545409SYNERGISTIC ANTIBACTERIAL ACTIVITY OF MEDIUM POLARITY OILS IN COMBINATION WITH ANTIBACTERIAL AGENTS ON BACTERIAL BIOFILMSDecember 2021January 2023Allow1310NoNo
17611999LIGHT-CURING COMPOSITIONS FOR TREATING ONYCHOMYCOSIS (FUNGAL NAIL INFECTION)November 2021February 2025Abandon3901NoNo
17453095VITAMIN D BASE LAYERNovember 2021April 2025Allow4150YesNo
17512251SYSTEM, METHOD, AND COMPOSITION FOR SKIN IMPROVEMENT AND TRANSIENT FLORA REDUCTIONOctober 2021May 2025Allow4231YesNo
17498881TOPICAL BARRIER COMPOSITION FOR DERMAL APPLICATIONOctober 2021November 2023Abandon2511NoNo
17442822SUNSCREEN COSMETICSeptember 2021July 2022Allow1011YesNo
17593732USE OF DIANHYDROHEXITOL FOR PRESERVING COSMETIC PREPARATIONSSeptember 2021March 2024Abandon3011NoNo
174477854-in-1 Facial and Body WipeSeptember 2021June 2024Abandon3310NoNo
17436555PROCESS FOR THE PREPARATION OF HAIR TREATMENT COMPOSITIONS CONTAINING ORGANIC C1-C6 ALKOXY SILANESSeptember 2021May 2025Abandon4401NoNo
17444958SKINCARE PRODUCT AND MULTI-DIMENSIONAL ASCORBIC ACID SERUM FORMULATION THEREFORAugust 2021October 2023Abandon2611NoNo
17428309FATTY ACID ESTERS AS ANTI-MALASSEZIA AGENTSAugust 2021January 2025Allow4121YesNo
17386641COMPOSITION COMPRISING AT LEAST ONE GLYCOSYLATED FLAVONOID AND ITS USE IN COSMETICS OR DERMATOLOGYJuly 2021January 2024Abandon3011NoNo
17386142TRANSFER-RESISTANT TOPCOAT COMPOSITIONJuly 2021January 2025Abandon4150YesNo
17375065SHINE ENHANCING SPRAY COMPOSITIONJuly 2021November 2024Abandon4041NoNo
17422492SURFACTANT COMPOSITIONJuly 2021May 2025Allow4721YesNo
17367220METHODS TO IDENTIFY AND TREAT CISPLATIN-RESISTANT OVARIAN CANCERJuly 2021October 2024Abandon3901NoNo
17360415COSMETIC COMPOSITION PROVIDING UNIQUE SENSATIONSJune 2021June 2025Allow4840YesYes
17418158SOLID HAIR CONDITIONING COMPOSITIONJune 2021September 2024Abandon3901NoNo
17354345PREPARATION OF A PHARMACEUTICAL COMPOSITION OF OLODATEROL, TIOTROPIUM BROMIDE AND BUDESONIDEJune 2021December 2022Abandon1721NoNo
17416145COSMETIC COMPOSITION FOR KERATIN FIBERS COMPRISING C14-20 FATTY ACID AND SEMICRYSTALLINE POLYMERJune 2021December 2023Abandon3011NoNo
17416245ANHYDROUS COSMETIC COMPOSITION COMPRISING A LIQUID FATTY SUBSTANCE, A SOLID FATTY SUBSTANCE AND A SURFACTANTJune 2021January 2025Abandon4301NoNo
17415547GENT FOR DYEING HAIR, CONTAINING AT LEAST ONE ORGANIC SILICON COMPOUND IJune 2021November 2024Abandon4101NoNo
17311954MICROEMULSION COMPOSITION, CURED MATERIAL THEREOF, AND COSMETIC CONTAINING THE CURED MATERIALJune 2021June 2024Abandon3621NoNo
17295030BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USEMay 2021May 2025Abandon4821NoNo
17294170COSMETIC COMPOSITION FOR IMPROVING FRAGRANCE PERSISTENCEMay 2021June 2025Allow4920YesNo
17315630COSMETIC COMPOSITION IN THE FORM OF A REVITALIZING AND TONING OIL-IN-WATER EMULSION FOR SKIN AND LIPSMay 2021March 2023Abandon2301NoNo
17289468CROSSLINKED MATERIALSApril 2021April 2025Allow4711YesNo
17225481Nano-Emulsion Cosmetic Composition In Which High Content Oils Are StabilizedApril 2021June 2024Abandon3830YesNo
17225634Manufacturing of Semi-Plastic Pharmaceutical Dosage UnitsApril 2021October 2023Allow3011NoNo
17281718ANGIOGENESIS PROMOTER AND THERAPEUTIC METHODMarch 2021August 2024Allow4011YesNo
17218945METHODS AND COMPOSITIONS FOR IMPROVING SKINMarch 2021June 2024Allow3921YesNo
17277924METHOD FOR PRODUCING GLYCERYL ETHER-CONTAINING COMPOSITION, AND GLYCERYL ETHER-CONTAINING COMPOSITIONMarch 2021January 2024Allow3431NoNo
17187084GEL STABILIZED O/W EMULSION WITH ALPHA-ARBUTIN AND AZELAIC ACID DISPERSIONFebruary 2021September 2024Allow4240NoYes
17268398SELF-HEALING OR SELF-REPAIRING FILM FORMING COMPOSITIONFebruary 2021July 2023Allow2920YesNo
17259982A PROCESS FOR MAKING PERSONAL CARE FORMULATIONJanuary 2021December 2023Abandon3530NoNo
17143215Hair and Scalp Treatment SolutionJanuary 2021October 2022Abandon2210NoNo
17141615FRESHNESS-RETENTIVE FILMJanuary 2021August 2024Abandon4330NoNo
17140755DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODSJanuary 2021November 2022Abandon2301NoNo
17139048COMPOSITION COMPRISING AT LEAST TWO FATTY ACID ESTERS OF (POLY)GLYCEROL, AND USE THEREOF IN COSMETICSDecember 2020November 2022Abandon2330NoNo
17126369TRANSPARENT COMPOSITION WITH SOLUBLE SCALP HEALTH ACTIVEDecember 2020August 2023Allow3220NoNo
17253400EMULSION COMPRISING A SILICONE RESIN, A LIQUID POLYOL AND PIGMENTS, PREPARATION OF THE EMULSION, AND PROCESS USING SAMEDecember 2020January 2025Abandon4941NoNo
15734851SURFACTANT FOR WATER-IN-OIL EMULSIONDecember 2020January 2023Allow2611YesNo
17104241Treatment of RhinitisNovember 2020October 2022Abandon2301NoNo
17056514PRESERVATION COMPOSITIONSNovember 2020December 2022Allow2521YesNo
17052729COSMETIC OIL THICKENER AND OIL-SOLUBLE COPOLYMERNovember 2020December 2023Abandon3711YesNo
17085496PHASE CHANGE COSMETIC COMPOSITIONOctober 2020January 2024Allow3941NoNo
17076388PRESSURE-SENSITIVE HYDROGEL AND METHOD OF USEOctober 2020October 2022Abandon2411YesNo
17048393POWDEROUS FORMULATIONOctober 2020May 2024Abandon4331NoNo
17047798ABSORBENT PRODUCTS WITH ANTI-BACTERIAL AND ANTI-ODOUR PROPERTIESOctober 2020July 2024Abandon4501NoNo
17047587EMULSIFYING COMPOSITION FOR COSMETIC USE FOR PRODUCING AN O/W PICKERING EMULSION AND PROCESS FOR PRODUCING THIS EMULSIONOctober 2020August 2023Allow3421NoNo
17066476METHODS FOR COSMETIC SKIN REMODELINGOctober 2020April 2025Abandon5441YesNo
17037180DERIVATIVES OF MENTHOL AND USES THEREOFSeptember 2020November 2022Allow2621YesNo
17042916TOPICAL PREPARATION CONTAINING VITAMIN K1 AND PREPARATION METHOD THEREOFSeptember 2020October 2021Allow1221YesNo
17024592Compositions and Methods for Wound TreatmentSeptember 2020February 2022Allow1720NoNo
16338691Gynecological vaginal wash for adjusting female vaginal microecology and preparation method thereofSeptember 2020March 2024Abandon6011YesNo
16968826COMPOSITION COMPRISING OPTICAL CLEARING AGENT FOR IMPROVING OPTICAL CHARACTERISTIC OF SKINAugust 2020January 2023Abandon2921NoNo
16947423METHODS FOR PROTECTING HAIR FOLLICLESJuly 2020April 2023Abandon3321NoYes
16927442FORTIFIED PLANT-BASED FORMULATIONSJuly 2020June 2023Abandon3520NoNo
16916496COSMETIC COMPOSITIONS HAVING STABILIZED RETINOLJune 2020August 2023Allow3831YesNo
16911598SPRAY-DRIED PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENT NANOPARTICLESJune 2020October 2020Allow400YesNo
16957434COMPOSITION FOR CONDITIONING KERATIN FIBERSJune 2020January 2024Allow4261NoNo
16955614DECORATIVE AQUEOUS COMPOSITION AND METHOD FOR PRODUCING SAMEJune 2020January 2023Abandon3121YesNo
16955003HAIR TREATMENT PROCESS USING A FLAVIN DERIVATIVE AND LIGHT RADIATIONJune 2020March 2023Abandon3331YesNo
16954504COSMETICJune 2020December 2022Abandon3021NoNo
16894258USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, COMPOUNDS, AND COMPOSITIONJune 2020January 2022Allow1920YesNo
16892423LOTEPREDNOL ETABONATE NANOPARTICLES IN THERMOREVERSIBLE GELS FOR ENHANCED THERAPEUTICSJune 2020February 2021Allow810NoNo
16769410APPLICATIONS OF AN ESTER ADDITIVE FROM BIODERIVED RAW MATERIALSJune 2020January 2025Abandon5521NoNo
16767930COSMETIC COMPOSITION FOR IMPROVING SKIN CONDITION COMPRISING MIXTURE OF BRASSICA OLERACEA VAR. ACEPHALA SEAWATER EXTRACT, NASTURTIUM OFFICINALE SEAWATER EXTRACT AND BETA VULGARIS ROOT SEAWATER EXTRACTMay 2020February 2023Abandon3331NoNo
16765533METHODS FOR PREPARING CURCUMINOID COMPOSITIONSMay 2020March 2022Allow2221YesNo
16765428THICKENED ONE-COMPONENT HAIR TONERMay 2020January 2023Abandon3221YesNo
16764754COSMETIC COMPOSITIONS IN PARTICULAR WITH ANTI-AGING EFFECT, COMPRISING A GREEN EXTRACT OF AFRAMOMUM ANGUSTIFOLIUM OR LONGOZA PLANTMay 2020November 2022Abandon3021NoNo
15931561INDUCTION OF A PHYSIOLOGICAL DISPERSION RESPONSE IN BACTERIAL CELLS IN A BIOFILMMay 2020April 2022Allow2311YesNo
16868199CRACKING AEROSOL COMPOSITIONMay 2020July 2023Abandon3831YesNo
16848814Drug Delivery Devices and Methods of Making and Using SameApril 2020February 2024Abandon4641YesNo
16755730METHOD OF USE OF PERSONAL CLEANSING COMPOSITIONSApril 2020February 2023Abandon3410NoNo
16844136Abuse-deterrent pharmaceutical compositionsApril 2020July 2021Abandon1511NoNo
16753593HAIRSTYLING COMPOSITIONApril 2020January 2024Allow4541YesYes
16652469INVERSE EMULSION THICKENERSMarch 2020October 2021Allow1901YesNo
16651878ANTIOXIDIZING, ANTIAGING, OR ANTI-INFLAMMATORY COMPOSITION FOR STRENGTHENING SKIN BARRIER AND CARING FOR SKIN CELL DAMAGE CAUSED BY FINE DUST INCLUDING FERMENTED TEA EXTRACTMarch 2020June 2025Abandon6061YesNo
16649398OIL-IN-WATER EMULSION COSMETIC USING ULTRAMICROEMULSIONMarch 2020August 2022Abandon2811NoNo
16648334UREA GROUP-CONTAINING ORGANOPOLYSILOXANE, METHOD FOR MANUFACTURING UREA GROUP-CONTAINING ORGANOPOLYSILOXANE, AND COSMETICMarch 2020June 2022Abandon2721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERRIOS, JENNIFER A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
30
Examiner Affirmed
24
(80.0%)
Examiner Reversed
6
(20.0%)
Reversal Percentile
29.8%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
127
Allowed After Appeal Filing
28
(22.0%)
Not Allowed After Appeal Filing
99
(78.0%)
Filing Benefit Percentile
26.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BERRIOS, JENNIFER A - Prosecution Strategy Guide

Executive Summary

Examiner BERRIOS, JENNIFER A works in Art Unit 1613 and has examined 853 patent applications in our dataset. With an allowance rate of 39.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner BERRIOS, JENNIFER A's allowance rate of 39.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BERRIOS, JENNIFER A receive 2.43 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BERRIOS, JENNIFER A is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by BERRIOS, JENNIFER A. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.0% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.1% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 61.0% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 55.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 64.5% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.